RT Journal Article
SR Electronic
T1 Copy number variant detection with low-coverage whole-genome sequencing is a viable alternative to the traditional array-CGH
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.07.20183665
DO 10.1101/2020.09.07.20183665
A1 Kucharík, Marcel
A1 Budiš, Jaroslav
A1 Hýblová, Michaela
A1 Minárik, Gabriel
A1 Szemes, Tomáš
YR 2021
UL http://medrxiv.org/content/early/2021/03/21/2020.09.07.20183665.abstract
AB Copy number variations (CNVs) are a type of structural variants involving alterations in the number of copies of specific regions of DNA, which can either be deleted or duplicated. CNVs contribute substantially to normal population variability; however, abnormal CNVs cause numerous genetic disorders. Nowadays, several methods for CNV detection are used, from the conventional cytogenetic analysis through microarray-based methods (aCGH) to next-generation sequencing (NGS). We present GenomeScreen – NGS-based CNV detection method for lowcoverage whole-genome sequencing. We determined the theoretical limits of its accuracy and confirmed it with extensive in-silico study and real patient samples with known genotypes. Theoretically, at least 6M uniquely mapped reads are required to detect CNV with a length of 100 kilobases (kb) or more with high confidence (Z-score > 7). In practice, the in-silico analysis showed the requirement of at least 8M to obtain >99% accuracy (for 100 kb deviations). We compared GenomeScreen with one of the currently used aCGH methods in diagnostic laboratories, which has a 200 kb mean resolution. GenomeScreen and aCGH both detected 59 deviations, GenomeScreen furthermore detected 134 other (usually) smaller variations. The performance of the proposed GenemoScreen tool is comparable or superior to the aCGH regarding accuracy, turnaround time, and cost-effectiveness, presenting a reasonable benefit particularly in a prenatal diagnosis setting.Competing Interest StatementWe declare a potential competing financial interest in the form of employee contracts (see affiliations for each author) with Geneton Ltd. and TrisomyTest Ltd. Geneton Ltd. participated in the development of a commercial NIPT test in Slovakia; however, it is not a provider of this commercial test, but continues to do basic and applied research in the field of NIPT. On the other hand, TrisomyTest Ltd. is the commercial provider of NIPT testing in Slovakia. Its participation in the study was limited to the routine NIPT testing that generated the genomic results reused in our research. Related to this work, there are no patents, products in development, or marketed products to declare. The authors declare no other conflict of interest.Clinical TrialEach included individual agreed to use of their genomic data in an anonymized form for general biomedical research. The NIPT study (study ID 35900_2015) was approved by the Ethical Committee of the Bratislava Self-Governing Region (Sabinovska ul.16, 820 05 Bratislava) on 30th April of 2015 under the decision ID 03899_2015.Funding StatementThis publication was supported by the project "Long term strategic research and development focused on the occurrence of Lynch syndrome in the Slovak population and possibilities of prevention of tumors associated with this syndrome" (ITMS 313011V578) co-financed by the European Regional Development Fund (ERDF). The article was also created with the support of the OP Integrated Infrastructure for the project: Introduction of an innovative test for screening and monitoring of cancer patients - GenoScan LBquant, ITMS: NFP313010Q927, co-financed by the ERDF. The data infrastructure was built with the support of the Operational Program Integrated Infrastructure within the project: "Horizontal ICT support and centralized infrastructure for research and development institutions", ITMS code 313011F988, co-financed by the ERDF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Each included individual agreed to use of their genomic data in an anonymized form for general biomedical research. The NIPT study (study ID 35900_2015) was approved by the Ethical Committee of the Bratislava Self-Governing Region (Sabinovska ul.16, 820 05 Bratislava) on 30th April of 2015 under the decision ID 03899_2015.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and scripts (Python 3.7) are available on the website https://github.com/marcelTBI/GenomeScreen . https://github.com/marcelTBI/GenomeScreen AbbreviationsaCGHarray-based comparative genomic hybridizationCBScircular binary segmentationCNVcopy number variantNGSnext-generation sequencingNIPTnon-invasive prenatal testingWGSwhole-genome sequencing